[go: up one dir, main page]

ZA200402323B - Process for making substituted pyrazoles. - Google Patents

Process for making substituted pyrazoles. Download PDF

Info

Publication number
ZA200402323B
ZA200402323B ZA200402323A ZA200402323A ZA200402323B ZA 200402323 B ZA200402323 B ZA 200402323B ZA 200402323 A ZA200402323 A ZA 200402323A ZA 200402323 A ZA200402323 A ZA 200402323A ZA 200402323 B ZA200402323 B ZA 200402323B
Authority
ZA
South Africa
Prior art keywords
process according
mixture
pyrazole
substituted
substituted pyrazole
Prior art date
Application number
ZA200402323A
Other languages
English (en)
Inventor
Kimberley C Allen
John E Baldus
Albert D Edney
Lisa L Mcdermott
Partha S Mudipalli
Shaun R Selness
Shekhar Viswanath
Dan R Dukesherer
Gopichand Yalamanchili
Dennis K Anderson
Jerry D Clark
Patrick H Lau
Moe Czarnik Jodi
Win Naing
Christine B Seymour
John K Walker
Michael K Mao
Tobin C Schilke
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ZA200402323B publication Critical patent/ZA200402323B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200402323A 2001-09-25 2004-03-24 Process for making substituted pyrazoles. ZA200402323B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32498701P 2001-09-25 2001-09-25

Publications (1)

Publication Number Publication Date
ZA200402323B true ZA200402323B (en) 2005-04-29

Family

ID=23265959

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200402323A ZA200402323B (en) 2001-09-25 2004-03-24 Process for making substituted pyrazoles.

Country Status (8)

Country Link
US (1) US6872725B2 (ja)
EP (1) EP1429772A1 (ja)
JP (1) JP2005529060A (ja)
BR (1) BR0212822A (ja)
CA (1) CA2461080A1 (ja)
MX (1) MXPA04002762A (ja)
WO (1) WO2003026662A1 (ja)
ZA (1) ZA200402323B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
PE20070823A1 (es) * 2005-11-15 2007-08-09 Glaxo Group Ltd Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona
PL2350046T3 (pl) * 2008-11-14 2014-05-30 Fmc Agro Singapore Pte Ltd Sposób otrzymywania niehydratowalnej postaci krystalicznej

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU677783B2 (en) 1992-06-10 1997-05-08 Elan Pharma International Limited Surface modified nsaid nanoparticles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors

Also Published As

Publication number Publication date
WO2003026662A1 (en) 2003-04-03
US6872725B2 (en) 2005-03-29
MXPA04002762A (es) 2004-06-29
CA2461080A1 (en) 2003-04-03
BR0212822A (pt) 2005-08-30
US20030153583A1 (en) 2003-08-14
EP1429772A1 (en) 2004-06-23
JP2005529060A (ja) 2005-09-29

Similar Documents

Publication Publication Date Title
AU755498B2 (en) 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
JP6286409B2 (ja) Ａｘｌインヒビターとして有用な置換トリアゾール
JP5597353B2 (ja) 置換ピラゾール化合物
TWI469983B (zh) 用於治療神經病症之咪唑並［５，１－ｆ］［１，２，４］三類
US10202390B2 (en) Heteroaryl substituted aminopyridine compounds
AU2005321946A1 (en) Enzyme modulators and treatments
CA2351725A1 (en) Substituted pyrazoles as p38 kinase inhibitors
MXPA02003533A (es) Derivados de pirimidina.
BG60865B1 (bg) Триазолови фунгицидни съединения и метод за получаването им
WO2014109414A1 (ja) 含窒素複素環化合物またはその塩
MXPA04011638A (es) Derivados de pirazol como inhibidores de la quinasa p38.
CA2923393A1 (en) Novel soluble guanylate cyclase activators and their use
US12233065B2 (en) Inhibitors of RNA helicase DHX9 and uses thereof
NZ571441A (en) Triazolone derivative
KR100998816B1 (ko) 신규한 항진균성 트리아졸 유도체
WO2005023782A1 (ja) 置換された縮環ピリミジン－４（３ｈ）－オン化合物
AU2002330096B2 (en) Process for making substituted pyrazoles
AU2002330096A1 (en) Process for making substituted pyrazoles
ZA200402323B (en) Process for making substituted pyrazoles.
CA2487948A1 (en) Azole methylidene cyanide derivatives and their use as protein kinase modulators
WO2015197188A1 (en) Pyrazolyl-based carboxamides as crac inhibitors
US7057049B2 (en) Process for making substituted pyrazoles
TW391965B (en) Triazole derivatives and antifungic pharmacentical compositions